Immune Checkpoint Inhibitors in the Treatment of Stage III NSCLC

Download this slideset to review the latest clinical data supporting the optimal use of checkpoint inhibitor therapy in patients with stage III NSCLC, including expert guidance on management of immunotherapy-related pulmonary toxicity.
Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD
Mark A. Socinski, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.36 MB
Released: October 21, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Related Content

Webcast of a CCO symposium at CHEST 2019 featuring expert perspectives on optimal integration of immunotherapy into stage III NSCLC care using a multidisciplinary approach

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit US Physicians: maximum of 1.0 Medical Knowledge MOC point(s) Released: November 20, 2019 Expired: No longer available for credit

In this slideset, a multidisciplinary panel provides an overview of stage III NSCLC, including insights on optimal staging, chemoradiation therapy, and radiation techniques.

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Released: October 21, 2019

In this slideset, a multidisciplinary expert panel provides insights on optimal use of checkpoint inhibition in the treatment of a series of patient cases with stage III NSCLC.

Gerard A. Silvestri, MD, MS
Program Director
Kristin Higgins, MD Mark A. Socinski, MD
Released: October 21, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue